Can brensocatib (Brinsupri) be added to Jascayd (azithromycin)?

Can Brensocatib (Brinsupri) Be Added to Azithromycin (Jascayd)?

Yes, brensocatib can be added to azithromycin based on available evidence, though no direct drug interaction data exists between these specific agents. The FDA label for Jascayd (nerandomilast, not azithromycin) does not list brensocatib as a contraindication, and brensocatib's drug interaction profile shows no concerning interactions with macrolides 1.

Key Considerations for Combination Use

Drug Interaction Profile

Brensocatib is primarily metabolized by CYP3A4 and is a substrate of P-glycoprotein (P-gp) 1. The critical interaction to note:

• Clarithromycin (a macrolide like azithromycin) increased brensocatib exposure by 55% (AUC) and 68% (Cmax) when used as a strong CYP3A4/P-gp inhibitor 1
• However, azithromycin has minimal CYP3A4 inhibitory effects compared to clarithromycin or erythromycin 2
• Azithromycin does not share the significant drug interaction profile of other macrolides 2

Clinical Context Matters

For bronchiectasis patients: Long-term macrolide therapy (azithromycin or erythromycin) is recommended for adults with three or more exacerbations per year 3. Brensocatib is approved for non-cystic fibrosis bronchiectasis to reduce exacerbations 4. These agents target different mechanisms:

• Azithromycin: Anti-inflammatory and immunomodulatory effects, reduces exacerbations 3
• Brensocatib: Inhibits dipeptidyl peptidase 1 (DPP1), reducing neutrophil serine protease activity 5, 4

Practical Recommendations

If combining brensocatib with azithromycin:

1. No dose adjustment of brensocatib is necessary - Unlike clarithromycin, azithromycin's weak CYP3A4 effects make clinically significant interaction unlikely
2. Monitor for additive gastrointestinal effects - Both agents can cause diarrhea and nausea 3, 6
3. Watch for QTc prolongation - Macrolides carry this risk, though azithromycin is lower risk than other macrolides 3

Important Caveats

• The question appears to confuse drug names: "Jascayd" is actually nerandomilast (a PDE4B inhibitor for pulmonary fibrosis), not azithromycin 6, 7
• If the actual question is about combining brensocatib with Jascayd (nerandomilast): There is no evidence or drug interaction data for this combination, as they treat different conditions (bronchiectasis vs. pulmonary fibrosis)

Monitoring Parameters When Combining

• Gastrointestinal symptoms (diarrhea, nausea) - most common with both agents
• Weight changes - brensocatib can cause weight decrease 6
• Macrolide resistance development - occurs with long-term azithromycin use (88% resistance after 12 months) 3, 8
• Hearing changes or tinnitus - potential with both aminoglycosides and macrolides 3

Bottom line: Brensocatib and azithromycin can be used together for bronchiectasis management without dose adjustment, targeting complementary pathways of neutrophilic inflammation. The combination may offer additive benefit in reducing exacerbations, though formal studies of this specific combination are lacking.